Claudia Moore, M.Sc. Email and Phone Number

Whether I’m developing clinical strategies, working with patient advocacy groups, listening to physician needs, managing complex global projects, or overseeing vendors, my focus remains the same: How can we make this work better for the patients we serve and the teams we support? I’m the go-to Clinical Operations leader for mission-critical projects that demand a passion for patient engagement. Working closely with rare disease communities taught me that patient success and successful product adoption depends on building strong relationships with key opinion leaders, understanding the patient journey, and creating support systems that address real patient needs. Through this patient-centric approach, i've led frameworks that increased patient participation across multiple rare disease trials while driving operational excellence. I've led the clinical portion of presentations that secured board approval for clinical programs worth up to $195 million, while simultaneously driving $37 million in early vendor negotiation savings. My expertise spans clinical strategy development, patient advocacy engagement, end-to-end clinical project management, people management, and vendor oversight. I have a history of de-risking medical product development from early innovation through market approval. By fostering relationships with key stakeholders, patient advocacy organizations, and physicians, I have enabled the successful delivery of clinical projects globally for complex pharmaceuticals and medical devices. My expertise lies in accelerating medical product development by enabling clinical project teams to become decision-makers, leveraging data to support decision-making, embracing synergies from diverse expertise, and rapidly adapting workflows for optimal efficiency. Reporting to the Senior VP of Clinical Development and Operations, I successfully managed a global clinical program focused on investigating a small molecule treatment for Spinocerebellar Ataxia 3, Amyotrophic Lateral Sclerosis, and Huntington's disease. I partnered with key stakeholders to identify patient population needs and leveraged data to drive adaptation to decentralized models. These efforts increased patient access and participation by 90%. In my previous roles at Thermo Fisher Scientific, Edwards Lifesciences, and Medtronic, I have consistently demonstrated my ability to lead cross-functional teams, mentor direct reports, drive innovation, and successfully manage multiple projects and priorities in fast-paced and highly matrix environments.